TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31475938
Drug: Combined application
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined application of scapular mobilization and manual posterior capsule stretching (n=54)
Study: 29214925
Drug: ISO +
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO + EXE (100 mg of isoflavone and exercise)
Study: 25994188
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection loading (100 ml 5% glucose injection + 50 ml Shenfu injection)
Study: 25994188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (150 ml 5% glucose injection)
Study: 24952857
Drug: NT‐proBNP-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP-guided treatment
Study: 11943102
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no effect on H. pylori infection)
Study: 9649995
Drug: Vecuronium (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.12 mg kg‐1)
Study: 8543493
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 h (n = 77)
Study: 8543493
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g and metronidazole 500 mg every 8 h (n = 83)
Study: 6797288
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (group II)
Study: 29153415
Drug: Formoterol (FOM)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol (FOM) DPI (9 μg via a Turbuhaler®)
Study: 25986615
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (1×10^8 CFU for five days) + Oral Rehydration Solution (ORS)
Study: 29941406
Drug: Fixed-dose bictegravir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide
Study: 24752322
Drug: PVC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVC group (propofol infusion via a 1‐m PVC infusion extension tube)
Study: 22261236
Drug: Four treatment
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four treatment regimens for NGU
Study: 18506317
Drug: Dexmedetomidine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg), plus dexmedetomidine, 1 mg x kg‐1
Study: 18506317
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg)
Study: 8757002
Drug: Linomide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide (2.5 mg daily)
Study: 21409494
Drug: Conivaptan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan (20 mg single dose)
Study: 16782422
Drug: Calcium (750
Normalized name: calcium carbonate 300 mg calcium (750 mg) ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (750 mg), Vitamin K1 (1.0 mg), Vitamin D3 (10.0 microg)
Study: 14668280
Drug: High-bioavailability diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-bioavailability diet (13.1 mg/d nonheme iron, 2.0 mg/d heme iron)
Study: 14668280
Drug: Low-bioavailability diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-bioavailability diet (14.8 mg/d nonheme iron, 0.3 mg/d heme iron)
Study: 20943877
Drug: V710 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: V710 30 μg
Study: 20943877
Drug: V710 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: V710 90 μg
Study: 20943877
Drug: V710 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: V710 5 μg
Study: 17559843
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of embryo culture supernatant (ECS)
Study: 15880336
Drug: VEGF +405
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF +405 CC genotype
Study: 8934727
Drug: FAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC regimen (5‐FU 600 mg/m2 i.v. over 1 hour, DOX 50 mg/m2 i.v. bolus, CPM 400 mg/m2 i.v. bolus)
Study: 8934727
Drug: FULON regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FULON regimen (5‐FU 250 mg/m2 per day continuously infused, CPM 300 mg/m2 i.v. bolus, DOX 15 mg/m2 i.v. bolus)
Study: 2693027
Drug: Gangliosides (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides (100 mg daily, 5 days per week for 12 weeks)
Study: 690219
Drug: Insight therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight therapy group
Study: 31521754
Drug: Low-dose, Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, Early Fresh Frozen Plasma Transfusion (LEFT) therapy (5 mL/kg body weight)
Study: 31521754
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NO LEFT group) (5 mL/kg body weight)
Study: 21677600
Drug: everolimus +
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus + reduced calcineurin inhibitor (CNI)
Study: 18405405
Drug: Xylometazoline hydrochloride
Normalized name: Xylometazoline Hydrochloride
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylometazoline hydrochloride 0.1 per cent nasal spray
Study: 18405405
Drug: Xylometazoline hydrochloride
Normalized name: Xylometazoline Hydrochloride
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylometazoline hydrochloride 0.1 per cent nasal spray (in septoplasty patients)
Study: 2858711
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.75 mg/kg over 90 min
Study: 2858711
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase at a dosage of 1,500,000 IU over 60 min
Study: 30141364
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.025% otic solution, administered twice daily for 7 days
Study: 30141364
Drug: Placebo otic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo otic solution, administered twice daily for 7 days
Study: 30141364
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.025% otic solution
Study: 30141364
Drug: Placebo otic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo otic solution
Study: 24668360
Drug: Body awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body awareness therapy (group sessions once a week for eight weeks)
Study: 22425702
Drug: SCY‐635 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCY‐635 900 mg/d
Study: 11513186
Drug: i.v. glycyrrhizin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. glycyrrhizin treatment three times per week for 4 weeks
Study: 11513186
Drug: i.v. glycyrrhizin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. glycyrrhizin treatment six times per week for 4 weeks
Study: 8427942
Drug: Hymecromone 400
Normalized name: hymecromone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 400 mg infused i.v. over 3 min
Study: 8427942
Drug: Hymecromone 800
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 800 mg infused i.v. over 5 min
Study: 8427942
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of hymecromone
Study: 25015747
Drug: L-carnitine 3g
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine 3g daily plus 250 mg clomiphene citrate
Study: 25015747
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 250 mg clomiphene citrate
Study: 12791633
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of protein intake (72 g/d)
Study: 2404636
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg t.i.d.)
Study: 31099911
Drug: Chronic glucocorticoid
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic glucocorticoid (GC) treatment
Study: 27390369
Drug: ATZ/LNG 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATZ/LNG 500 µg/20 µg (low dose)
Study: 27390369
Drug: ATZ/LNG 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATZ/LNG 1000 µg/30 µg (mid dose)
Study: 27390369
Drug: ATZ/LNG 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATZ/LNG 1500 µg/40 µg (high dose)
Study: 15767846
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg
Study: 11547542
Drug: 28% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28% oxygen for the first 36 postoperative hours (treatment group, n = 13)
Study: 9626884
Drug: Gadolinium (Gd)
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium (Gd) administered first in the same session (7 patients)
Study: 9626884
Drug: Ferumoxide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxide administered first in the same session (3 patients)
Study: 9626884
Drug: Gadolinium administered
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium administered in separate session (3 patients)
Study: 9626884
Drug: Gadolinium administered
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium administered first in separate session (3 patients)
Study: 8179371
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (5 g) before cardiopulmonary bypass
Study: 3067743
Drug: Trabeculectomy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy at diagnosis followed by supplementary medical therapy (group B)
Study: 3067743
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment followed by trabeculectomy if unsuccessful (group A)
Study: 3067743
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (group A)
Study: 31277913
Drug: Proactive enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive enteral nutrition (EN) via nasogastric (NG) feeding, commenced at 30 ml/h after stem cell infusion, increased to goal as oral intake declined.
Study: 31277913
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (parenteral nutrition, PN) commenced when oral intake was ≤60% of requirements for three days.
Study: 27497379
Drug: Antibiotic consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic consumption (betalactams and amoxicillin)
Study: 27497379
Drug: Antibiotic consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic consumption
Study: 23780505
Drug: Generic (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic (test) formulation of betamethasone injectable suspension
Study: 23780505
Drug: Branded (reference)
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded (reference) formulation of betamethasone injectable suspension
Study: 20094043
Drug: pramlintide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pramlintide + sibutramine (10 mg q.a.m.)
Study: 20094043
Drug: pramlintide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pramlintide + phentermine (37.5 mg q.a.m.)
Study: 18566793
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy including transurethral resection (TUR-B), open partial cystectomy, chemotherapy (intravesical or systemic), local radiation, and minimally invasive interventional therapies.
Study: 18566793
Drug: Conservative or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative or less invasive treatment approaches (specific interventions not detailed).
Study: 16501948
Drug: Locally applied
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally applied nasal decongestant agents: 2 drops twice/day of xylometazoline nasal solution 0.1% and 100microg budesonide (NDCA group, n=39)
Study: 10198296
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 5, 12 units daily for 5 days
Study: 10198296
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 1, 12 units for 1 day
Study: 2110271
Drug: 3.2 mg
Normalized name: menthol 3.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg rt-PA
Study: 2110271
Drug: 6.4 mg
Normalized name: menthol 6.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 mg rt-PA
Study: 2110271
Drug: 12.8 mg
Normalized name: alanine 12.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.8 mg rt-PA
Study: 2110271
Drug: 25.6 mg
Normalized name: SALICYLIC ACID 25.6 mg in 100 TOPICAL PATCH [SINSINPAS CORN REMOVER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25.6 mg rt-PA
Study: 2110271
Drug: 33.3 mg
Normalized name: caffeine 33.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33.3 mg rt-PA
Study: 2110271
Drug: 50.0 mg
Normalized name: ZINC OXIDE 50.0 mg in 1 mL TOPICAL CREAM [Mineral Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.0 mg rt-PA
Study: 552293
Drug: Lignocaine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (oral administration)
Study: 552293
Drug: Lignocaine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (intravenous administration)
Study: 28179230
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose computed tomography (CT) screening
Study: 25791144
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral therapy (CBT) sessions (n = 45)
Study: 21233606
Drug: Steroids group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids group (n = 105) - received 500 mg hydrocortisone immediately before hepatic‐pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3
Study: 21233606
Drug: Steroids group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids group
Study: 20064183
Drug: Subdermal, pulsed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal, pulsed, 1064‐nm Nd:YAG laser treatment
Study: 20064183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1064‐nm Nd:YAG laser and removal of cell debris by suction cannula
Study: 11259985
Drug: Chrysin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysin (400 mg oral dose)
Study: 9498885
Drug: Patient-Controlled Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Epidural Administration (PCEA)
Study: 9498885
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion
Study: 7893585
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg BTS 67 582
Study: 7893585
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg BTS 67 582
Study: 7893585
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg BTS 67 582
Study: 2822795
Drug: ACTH (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH (0.5 mg i.m; every 12 h)
Study: 2822795
Drug: Cortisol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (50 mg orally, every 6 h)
Study: 22843347
Drug: LHA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LHA intervention with behavioral counseling and nicotine patches
Study: 20930640
Drug: Drug Conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Conservation (DC) group
Study: 19299775
Drug: Subtenon block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon block (SB) with 0.06-0.08 mL/kg of 2% lidocaine and 0.5% bupivacaine (50:50) mixture and simultaneous 0.2 mL/kg normal saline IV
Study: 19299775
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IV F) 1 microg/kg (0.2 mL/kg of 5 microg/kg)
Study: 19299775
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IV F)
Study: 17582921
Drug: Human papillomavirus
Normalized name: human papillomavirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human papillomavirus vaccine (3-dose schedule: 0, 2, and 6 months)
Study: 9797204
Drug: Ritonavir 200
Normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 200 mg q12h with indinavir 800 mg q8h
Study: 9797204
Drug: Ritonavir 300
Normalized name: nirmatrelvir / ritonavir 300 MG /100 MG ; 150 MG / 100 MG Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 300 mg q12h with indinavir 600 mg q8h
Study: 9797204
Drug: Ritonavir 300
Normalized name: nirmatrelvir / ritonavir 300 MG /100 MG ; 150 MG / 100 MG Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 300 mg q12h with indinavir 400 mg q8h
Study: 9797204
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg q12h with indinavir 400 mg q8h
Study: 9797204
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg q8h (standard regimen)
Study: 8591964
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment schemes including individualized therapy based on risk factors.
Study: 8591964
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment for stage III and IV favorable histology Wilms tumor.
Study: 2528405
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (0.25 to 12 micrograms.min‐1)
Study: 349395
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no further treatment)
Study: 28939406
Drug: Amlodipine/Losartan Potassium/Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Losartan Potassium/Chlorthalidone (A/L/C)
Study: 28939406
Drug: Amlodipine/Losartan Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Losartan Potassium (A/L)
Study: 26154787
Drug: Guselkumab 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 5 mg
Study: 26154787
Drug: Guselkumab 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 15 mg
Study: 26154787
Drug: Guselkumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (all doses)
Study: 16504646
Drug: Rimonabant 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 1 mg
Study: 16504646
Drug: Rimonabant 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 3 mg
Study: 16504646
Drug: Rimonabant 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 10 mg
Study: 16504646
Drug: Rimonabant 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 30 mg
Study: 16504646
Drug: Rimonabant 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 90 mg
Study: 16504646
Drug: Rimonabant (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (any dose)
Study: 11058714
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day, n=24)
Study: 11058714
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day, n=26)
Study: 8406153
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet (Vivonex TEN 2.1 l/day for four weeks)
Study: 8406153
Drug: Prednisolone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.75 mg/kg/day for two weeks and subsequent reducing doses)
Study: 28915080
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg reslizumab IV Q4W
Study: 19447770
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) - two cycles at baseline and 24 weeks, each cycle consisting of four weekly infusions (375 mg/m²)
Study: 17851890
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with carboplatin and uracil‐f tegafur (UFT)
Study: 7827642
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate + transdermal estradiol
Study: 2907735
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of glafenine twice a day
Study: 2907735
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of paracetamol twice a day
Study: 31112605
Drug: Conversation-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversation-based intervention (daily 30-min face-to-face semi-structured conversations with trained interviewers for 6 weeks)
Study: 29668354
Drug: Pulsed high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high-intensity laser therapy three times per week for 8 weeks, along with usual hormonal treatment